Trial Profile
An open-label, randomized, parallel-group, cohort study to evaluate the safety and efficacy of bimatoprost 0.03% versus bimatoprost 0.01% eye drops in patients with glaucoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2015
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary)
- Indications Glaucoma; Open-angle glaucoma; Pigmentary glaucoma
- Focus Adverse reactions
- 13 Dec 2015 New trial record